{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:46:56Z","timestamp":1762955216011},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T00:00:00Z","timestamp":1366416000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40268-013-0013-9","type":"journal-article","created":{"date-parts":[[2013,4,19]],"date-time":"2013-04-19T11:19:18Z","timestamp":1366370358000},"page":"109-117","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of a Fixed Combination of Irbesartan\/Hydrochlorothiazide in Chinese Patients with Moderate to Severe Hypertension"],"prefix":"10.1007","volume":"13","author":[{"name":"on behalf of the INCENT Investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi-Fang","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Sheng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen-Shan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu-Yan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,20]]},"reference":[{"doi-asserted-by":"crossref","unstructured":"Wu Y, Huxley R, Li L, Anna V, Xie G, Yao C, Woodward M, Li X, Chalmers J, Gao R, Kong L, Yang X, China NNHS Steering Committee, China NNHS Working Group. Prevalence, awareness, treatment, and control of hypertension in China: data from the China National Nutrition and Health Survey 2002. Circulation. 2008;118:2679\u201386.","key":"13_CR1","DOI":"10.1161\/CIRCULATIONAHA.108.788166"},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1524-6175.2005.03793.x","volume":"7","author":"P Palatini","year":"2005","unstructured":"Palatini P. Combination therapy in the management of hypertension: focus on angiotensin receptor blockers combined with diuretics. J Clin Hypertens (Greenwich). 2005;7:96\u2013101.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1751-7176.2010.00397.x","volume":"13","author":"AH Gradman","year":"2011","unstructured":"Gradman AH, Basile JN, Carter BL, Bakris GL, American Society of Hypertension Writing Group. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011;13:146\u201354.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/HJH.0b013e328333146d","volume":"27","author":"G Mancia","year":"2009","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Cl\u00e9ment D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A, European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121\u201358.","journal-title":"J Hypertens"},{"issue":"39","key":"13_CR5","first-page":"579","volume":"2011","author":"Writing Group of the 2010 Chinese Guidelines for the Management of Hypertension","year":"2010","unstructured":"Writing Group of the 2010 Chinese Guidelines for the Management of Hypertension. Chinese guidelines for the management of hypertension (in Chinese). Chin J Cardiol. 2010;2011(39):579\u2013616.","journal-title":"Chin J Cardiol"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1016\/S0149-2918(03)80338-7","volume":"25","author":"A Coca","year":"2003","unstructured":"Coca A, Calvo C, Sobrino J, G\u00f3mez E, L\u00f3pez-Paz JE, Sierra C, Bragulat E, de la Sierra A. Once-daily fixed-combination irbesartan 300\u00a0mg\/ hydrochlorothiazide 25\u00a0mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther. 2003;25:2849\u201364.","journal-title":"Clin Ther"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.amjhyper.2005.06.009","volume":"18","author":"G Bobrie","year":"2005","unstructured":"Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R, COmparative Study of Efficacy of Irbesartan\/HCTZ with Valsartan\/HCTZ Using Home Blood Pressure Monitoring in the TreAtment of Mild-to-Moderate Hypertension (COSIMA) Investigators. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens. 2005;18:1482\u20138.","journal-title":"Am J Hypertens"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/147323000503300603","volume":"33","author":"JM Neutel","year":"2005","unstructured":"Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan\/hydrochlorothiazide and losartan\/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res. 2005;33:620\u201331.","journal-title":"J Int Med Res"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/j.1524-6175.2004.04720.x","volume":"7","author":"JM Neutel","year":"2005","unstructured":"Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, Weber MA, INCLUSIVE Investigators. The efficacy and safety of low- and high-dose fixed combinations of irbesartan\/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7:578\u201386.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/sj.jhh.1002293","volume":"22","author":"JM Neutel","year":"2008","unstructured":"Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A. A comparison of the efficacy and safety of irbesartan\/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension. J Hum Hypertens. 2008;22:266\u201374.","journal-title":"J Hum Hypertens"},{"doi-asserted-by":"crossref","unstructured":"Neutel JM, Franklin SS, Oparil S, Bhaumik A, Ptaszynska A, Lapuerta P. Efficacy and safety of irbesartan\/HCTZ combination therapy as initial treatment for rapid control of severe hypertension. J Clin Hypertens (Greenwich). 2006;8:850\u20137; quiz 858\u20139.","key":"13_CR11","DOI":"10.1111\/j.1524-6175.2006.05676.x"},{"key":"13_CR12","first-page":"430","volume":"19","author":"B Tang","year":"2004","unstructured":"Tang B, Zhu J, Cai N, Fan W, Sun N, Liu G, Ma H. Effect and safety of irbesartan\/hydrochlorothiazide combination therapy on mild to moderate essential hypertension (in Chinese). Chin Circ J. 2004;19:430\u20132.","journal-title":"Chin Circ J"},{"key":"13_CR13","first-page":"618","volume":"33","author":"NL Sun","year":"2005","unstructured":"Sun NL, Jing S, Chen J. The control rate of irbesartan\/hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension (in Chinese). Chin J Cardiol. 2005;33:618\u201321.","journal-title":"Chin J Cardiol"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1524-6175.2007.07195.x","volume":"10","author":"E Saunders","year":"2008","unstructured":"Saunders E, Cable G, Neutel J. Predictors of blood pressure response to angiotensin receptor blocker\/diuretic combination therapy: a secondary analysis of the Irbesartan\/Hydrochlorothiazide Blood Pressure Reductions in Diverse Patient Populations (INCLUSIVE) study. J Clin Hypertens (Greenwich). 2008;10:27\u201333.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13_CR15","first-page":"618","volume":"98","author":"EO Ofili","year":"2006","unstructured":"Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL, Cushman WC, Sowers JR, Weber MA. Irbesartan\/HCTZ fixed combinations in patients of different racial\/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006;98:618\u201326.","journal-title":"J Natl Med Assoc"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1076-7460.2007.07317.x","volume":"17","author":"WC Cushman","year":"2008","unstructured":"Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Madder R, Weber MA. Efficacy and safety of fixed combinations of irbesartan\/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008;17:27\u201336.","journal-title":"Am J Geriatr Cardiol"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S0027-9684(15)30876-2","volume":"101","author":"SG Chrysant","year":"2009","unstructured":"Chrysant SG, Neutel JM, Ferdinand KC. INCLUSIVE investigators. Irbesartan\/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J Natl Med Assoc. 2009;101:300\u20137.","journal-title":"J Natl Med Assoc"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1089\/jwh.2008.0499","volume":"17","author":"EO Ofili","year":"2008","unstructured":"Ofili EO, Cable G, Neutel JM, Saunders E. Efficacy and safety of fixed combinations of irbesartan\/hydrochlorothiazide in hypertensive women: the INCLUSIVE trial. J Womens Health (Larchmt). 2008;17:931\u20138.","journal-title":"J Womens Health (Larchmt)"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.clinthera.2008.12.018","volume":"30","author":"AJ Lewin","year":"2008","unstructured":"Lewin AJ, Weir MR. Antihypertensive efficacy and tolerability of irbesartan\/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan\/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clin Ther. 2008;30:2354\u201365.","journal-title":"Clin Ther"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1524-6175.2006.05486.x","volume":"8","author":"JR Sowers","year":"2006","unstructured":"Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, Weber MA, INCLUSIVE Investigators. Antihypertensive efficacy of Irbesartan\/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006;8:470\u201380.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/10641963.2010.496509","volume":"32","author":"R Asmar","year":"2010","unstructured":"Asmar R, Oparil S. Comparison of the antihypertensive efficacy of irbesartan\/HCTZ and valsartan\/HCTZ combination therapy: impact of age and gender. Clin Exp Hypertens. 2010;32:499\u2013503.","journal-title":"Clin Exp Hypertens"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.3109\/10641960902929420","volume":"31","author":"JM Neutel","year":"2009","unstructured":"Neutel JM, Franklin SS, Bhaumik A, Lapuerta P, Oparil S. Safety and tolerability of fixed-dose irbesartan\/hydrochlorothiazide for rapid control of severe hypertension. Clin Exp Hypertens. 2009;31:572\u201384.","journal-title":"Clin Exp Hypertens"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1751-7176.2010.00294.x","volume":"12","author":"SS Franklin","year":"2010","unstructured":"Franklin SS, Neutel JM. Efficacy and safety of irbesartan\/HCTZ in severe hypertension according to cardiometabolic factors. J Clin Hypertens (Greenwich). 2010;12:487\u201394.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"Suppl 5","key":"13_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1524-6175.2007.07805.x","volume":"9","author":"MR Weir","year":"2007","unstructured":"Weir MR, Neutel JM, Bhaumik A, De Obaldia ME, Lapuerta P. The efficacy and safety of initial use of irbesartan\/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. J Clin Hypertens (Greenwich). 2007;9(Suppl 5):23\u201330.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3810\/pgm.2011.07.2312","volume":"123","author":"JM Neutel","year":"2011","unstructured":"Neutel JM. A comparison of the efficacy and safety of irbesartan\/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review. Postgrad Med. 2011;123:126\u201334.","journal-title":"Postgrad Med"},{"issue":"Suppl 5","key":"13_CR26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1524-6175.2007.07808.x","volume":"9","author":"S Franklin","year":"2007","unstructured":"Franklin S, Lapuerta P, Cox D, Donovan M. Initial combination therapy with irbesartan\/hydrochlorothiazide for hypertension: an analysis of the relationship between baseline blood pressure and the need for combination therapy. J Clin Hypertens (Greenwich). 2007;9(Suppl 5):15\u201322.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2147\/VHRM.S3302","volume":"5","author":"P Bramlage","year":"2009","unstructured":"Bramlage P. Fixed combination of irbesartan and hydrochlorothiazide in the management of hypertension. Vasc Health Risk Manag. 2009;5:213\u201324.","journal-title":"Vasc Health Risk Manag"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2165\/00003495-200868100-00007","volume":"68","author":"JD Croxtall","year":"2008","unstructured":"Croxtall JD, Keating GM. Irbesartan\/Hydrochlorothiazide: in moderate to severe hypertension. Drugs. 2008;68:1465\u201372.","journal-title":"Drugs"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0013-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0013-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0013-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T08:09:07Z","timestamp":1715242147000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0013-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,20]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0013-9","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"type":"print","value":"1174-5886"},{"type":"electronic","value":"1179-6901"}],"subject":[],"published":{"date-parts":[[2013,4,20]]}}}